focus -WSS

focus

author：leisure time 2025-09-03 09:26:42 - browse：3

Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a handful of biotech companies are trying to develop next-generation, longer-lasting therapies based on a very different approach: RNA interference.

This Nobel Prize-winning science works by degrading the biological blueprints that RNA use to make proteins — without the genetic instructions, the troublesome proteins are never made and the gene is essentially muted.

If the companies succeed, it would be a significant shift in the obesity treatment revolution, away from weekly drugs targeting hormones to medications that could be given much less frequently — twice a year or even less — and pinpoint genetic contributors to weight.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Medicare Advantage overpayments discussion gets experts fired up

WSS

Wegovy trial has doctors encouraged over new possibilities

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

For Cytokinetics, FDA rejection of heart drug would help, not hinder

Maui's cultural, historic landmarks damaged in the devastating wildfires

Drastic changes should bring profitability, startup health insurers say

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

explore

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Psychedelics group wrestles with new pharma identity

Male doctors called my cancer incurable. A female doctor showed it wasn't

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

How to use technology to prevent future drug shortages

Psychedelics group wrestles with new pharma identity

Nonprofit, backed by Microsoft, to certify AI tools in health care

George Santos makes 1st court appearance after pleading not guilty to 13 counts

At JPM 2024, hospital systems pitch financial strength to investors

Novavax promises a turnaround & Lilly roils the obesity market

American taxpayers paid $1.8 trillion in health care costs in 2022

explore

Male doctors called my cancer incurable. A female doctor showed it wasn't

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

Physician assistants need a new name. Here's what it should be

NIH trials fail to test meaningful long Covid therapies, experts say

At JPM 2024, hospital systems pitch financial strength to investors

Anavex keeps shifting the goalposts in its clinical trials

focus

leisure time

leisure time

focus